Aesica Led Consortium Wins Technology Strategy Board Grant
News Apr 08, 2014
Aesica has led a consortium, also comprising Charnwood Technical Consulting, CatScI and Biocatalysts, which has successfully won a Technology Strategy Board grant directed at funding sustainable, high value chemical manufacturing achieved through industrial biotechnology.
The winning project is focused on establishing an industrial biotechnology process aimed at improving the sustainability of the manufacture of an active pharmaceutical ingredient (API).
The grant is designed to both assist commercial entities in trialling new processes and to create demonstration scale prototypes. The overall project, valued at £200,000, is scheduled for completion in 2014.
The funding for the project meets the Technology Strategy Board’s objective of fostering collaboration between the chemicals sector and industrial biotechnology developers, combining biological and chemical practices.
Biocatalysts will use “Design for Manufacture” principles to discover, develop and manufacture novel enzymes for the production of active pharmaceutical ingredients. CatScI will perform the proof of concept studies to assess the feasibility of a value-adding novel industrial biotechnology route to an active pharmaceutical ingredient.
Charnwood Technical Consulting will provide expertise to help design and scale-up the process, as well as guidance on quality and regulatory issues. Aesica will manage the overall project and carry out scale-up studies to determine the feasibility of the technology at larger scale.
Utilizing biocatalytic processes in the production of high value chemicals is environmentally friendly and forms part of an initiative to assist the chemicals industry in the shift away from dependency on fossil fuels towards a bio-economy based on renewable and biological compounds.
Dr Barrie Rhodes, Director of Technology Development at Aesica commented; “We are delighted that our project successfully secured such Technology Strategy Board funding and are naturally very pleased to be leading a consortium consisting of such highly experienced companies. At Aesica, we are committed to innovation and fostering effective partnerships to further good science. Indeed, bringing together such strong technical expertise and know-how to combine high value chemical manufacturing with industrial biotechnology is a prime example of what we are about.”
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018